Literature DB >> 35530285

A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.

Weihao Li1, Jian Zhou2, Tianqi Zhang3, Yi Tai1, Yanbo Xu1, Yanfang Bai4, Yu Jiang2, Zhenhai Lu1, Liren Li1, Jinhua Huang3, Zhizhong Pan1, Xiaojun Wu1, Jianhong Peng1, Junzhong Lin1.   

Abstract

An estimated 70-80% of cases of colorectal cancer liver metastasis (CRLM) are defined as initially unresectable. "Converting" to no evidence of disease (NED) status may prolong survival. The current study aimed to develop a novel scoring system that predicts the conversion outcome for initially unresectable CRLM. A total of 215 consecutive CRLM patients who received first-line systemic therapy from December 2012 to January 2020 at Sun Yat-sen University Cancer Center were enrolled in the internal cohort. Forty CRLM patients from the database of the Chinese Colorectal Cancer Multidisciplinary Team Alliance were enrolled in the external cohort. A logistic regression model was applied to identify risk factors associated with the conversion outcome. The tumor-to-liver volume ratio (TLVR) was calculated as the total tumor volume divided by the total liver volume, and its cutoff value was 0.23. Three predictors of conversion failure were identified in the internal cohort and incorporated into the C-NED score: poor tumor differentiation (1 point), number of liver metastases > 8 (1 point) and TLVR ≥ 0.23 (1 point). The conversion rate was significantly negatively associated with the C-NED score (P < 0.001). The C-indexes of the C-NED score for predicting successful conversion outcome in the internal cohort and external cohort were 0.734 (95% confidence interval (CI), 0.668-0.800) and 0.736 (95% CIs, 0.566-0.907), respectively. Median progression-free survival (PFS) time (P = 0.001) and overall survival (OS) time (P = 0.003) were statistically significant different among different C-NED score groups. Our study demonstrated that the C-NED score is an effective scoring system that indicates the actual conversion probability for initially unresectable CRLM patients before treatment, which can serve as a tool that guides optimal first-line management strategies. AJCR
Copyright © 2022.

Entities:  

Keywords:  Colorectal cancer; conversion outcome prediction; liver metastases; prognosis; three-dimensional reconstruction

Year:  2022        PMID: 35530285      PMCID: PMC9077072     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  37 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

2.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Clin Cancer Res       Date:  2019-06-20       Impact factor: 12.531

3.  Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.

Authors:  Kuniya Tanaka; Kazuya Nakagawa; Yasuhiro Yabushita; Yukihiko Hiroshima; Kenichi Matsuo; Mitsuyoshi Ota; Yasushi Ichikawa; Masataka Taguri; Mikiko Tanabe; Keiji Koda; Itaru Endo
Journal:  Surgery       Date:  2013-12-31       Impact factor: 3.982

4.  Long-Term Outcomes of Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases.

Authors:  Yoshiaki Maeda; Toshiki Shinohara; Akihisa Nagatsu; Noriaki Futakawa; Tomonori Hamada
Journal:  Ann Surg Oncol       Date:  2015-03-07       Impact factor: 5.344

5.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 7.  [Surgical management of hepatic metastases from colorectal cancer].

Authors:  L Chiche
Journal:  J Chir (Paris)       Date:  2003-04

8.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

9.  Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.

Authors:  Marin Strijker; Eline C Soer; Matteo de Pastena; Aafke Creemers; Alberto Balduzzi; Jamie J Beagan; Olivier R Busch; Otto M van Delden; Hans Halfwerk; Jeanin E van Hooft; Krijn P van Lienden; Giovanni Marchegiani; Sybren L Meijer; Carel J van Noesel; Roy J Reinten; Eva Roos; Sandor Schokker; Joanne Verheij; Marc J van de Vijver; Cynthia Waasdorp; Johanna W Wilmink; Bauke Ylstra; Marc G Besselink; Maarten F Bijlsma; Frederike Dijk; Hanneke W van Laarhoven
Journal:  Int J Cancer       Date:  2019-08-13       Impact factor: 7.396

Review 10.  Precision medicine becomes reality-tumor type-agnostic therapy.

Authors:  Li Yan; Wei Zhang
Journal:  Cancer Commun (Lond)       Date:  2018-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.